No, not an April Fools’ joke - BioBridge Ltd, the Cambridge-based independent life science innovation consultancy, was founded in 1989 and has been at the forefront of biotechnology and life science advances since then, from a ground-breaking report for Frost&Sullivan on biotechnology in animal breeding and production, via helping establish new approaches to xenogeneic therapies and biopharming, to current involvement in the latest green and blue biotechnology advances.
Dr Meredith Lloyd-Evans, founder and CEO of BioBridge Ltd, said “Since we started, we have worked with over 100 clients from individuals to giant corporations through start-ups and SMEs to governments, spread over the world from Japan via Europe to Canada and the East coast of America. Using our expertise in innovation and exploitation in Life Sciences, we’ve been able to work with and help creative people and companies build strong advances in marine and crop biotechnology, tissue engineering, animal health, medical devices and industrial biotechnology. Our expertise allows us to carry out highly-focused projects for companies on specific topics, and the breadth of experience means we can offer support to strategic decisions at top level, as well. We are very grateful to our clients for their support, especially our long-term relationships stretching from 10 to 25 years. Though our clientele is international, I’m also pleased to have helped the original ERBI, now One Nucleus, create its member purchasing scheme and provide the support to get this off the ground, to the benefit of our local biotech community.”
Looking to the future, Meredith is strongly involved in efforts to build sustainable economies based on marine and aquaculture biomass, in areas such as blue bioproducts for chemical, plastics and health uses, and is helping create European and international groupings to achieve this, via the BioMarine organisation. In Animal Health, he is working with the US-based Vaxiam Group to accelerate productive linkages between European and Chinese companies and research activities. In dermatological healthcare, BioBridge has successfully helped companies find new ingredients, especially from natural sources, and new products for management of long-term skin conditions. Work, and the opportunity to contribute to progress, does not stop!
Notes for Editors
BioBridge is one of the longest-established small independent innovation consultancies in Cambridge, with expertise in product strategy, business strategy, technology analysis and market dynamics as well as regulatory strategy. Clients are international in many life science sectors. Meredith trained as a vet, worked in veterinary practice in Canada and UK and in the animal pharma industry and then in IP management with British Technology Group. He worked briefly for PA Technology before setting up BioBridge in 1989. He has contributed to the UK Technology Strategy Board’s and NERC’s KTNs as Technology Transfer Manager, worked on projects funded by the EU’s DG MARE and DG Research, and provides licensing-in assistance for Japanese pharma companies, regulatory foresight for biomaterials companies, and project and proposal evaluation, as well as business developments and diversifications.
Meredith Lloyd-Evans, BioBridge Email: mlloydevans@biobridge.co.uk, Tel: +44 1223 566850